Weight Loss

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This comparison article is for educational and informational purposes only. Pricing, program details, and availability for all platforms cited are subject to change; verify current details directly with each provider. This article does not constitute medical advice. Compounded medications require evaluation by a licensed healthcare provider.

How to Read a GLP-1 Telehealth Comparison Honestly

The GLP-1 telehealth market has more than a dozen active platforms and a comparison landscape dominated by affiliate-driven content that ranks providers based on commission rates rather than program quality. This comparison uses five criteria that actually matter for patients: verified all-in pricing (not just the introductory rate), coaching structure and documented quality, pharmacy transparency, medication access (compounded vs. brand-name options), and program flexibility (month-to-month vs. prepay commitment). RNK Health is evaluated against competitors on these criteria using publicly available information as of publication.

For the full RNK Health program assessment, see the complete editorial review. For context on what compounded GLP-1 medications are, see our educational guide. For side effect considerations relevant across all platforms, see the safety guide.

The Comparison Framework

Five criteria, equally weighted in the editorial assessment: (1) Verified all-in monthly pricing at the semaglutide and tirzepatide tier — not the first-month promotional rate, but the ongoing rate at a starting dose. (2) Coaching structure — included vs. add-on, documented format and frequency, or absent. (3) Pharmacy transparency — is the compounding pharmacy identified? Is 503A/503B status disclosed or verifiable? (4) Medication access — compounded only, or access to brand-name FDA-approved options with insurance navigation. (5) Program flexibility — month-to-month or prepay commitment; cancellation terms.

Criteria that are NOT in this comparison: star ratings from review aggregators (subject to manipulation and selection bias), before/after testimonials (not clinical evidence), and promotional pricing that requires coupon codes not prominently disclosed on the main product page.

RNK Health

Injectable semaglutide: $197/month. Oral semaglutide: $198/month. Tirzepatide: $297/month. All prices all-inclusive — medication, physician oversight, personal coaching, supplies, shipping. Month-to-month, no contract. 48-hour delivery. All 50 states. Pharmacy disclosed (Springville, UT). No brand-name medication access based on available information.

Editorial assessment: Strong all-in pricing transparency, coaching included as standard at a competitive price point, pharmacy address disclosed, flexible commitment model. The gap: no documented coaching credential standards, no brand-name medication pathway for patients whose insurance may cover Wegovy or Zepbound.

Eden Health

Eden Health offers compounded semaglutide and tirzepatide with flat-rate pricing (does not increase with dose changes, which is a meaningful differentiator as patients titrate up), included coaching, and a 24/7 health coach access feature. Trade-offs: requires a 3-month prepaid commitment; labs are not included in the monthly rate and must be obtained separately. Tirzepatide pricing around $249/month (first month) and ongoing rates around $349/month on month-to-month basis, based on publicly available information. Month-to-month flexibility is less than RNK Health's model. The 24/7 coach access is a genuine differentiator for patients who want immediate support rather than scheduled touchpoints.

Noom Med

Noom Med operates differently from most compounded GLP-1 platforms: its primary offering is brand-name tirzepatide (Zepbound) with insurance support and a same-day prescription model, plus a sophisticated behavior change app (Welli AI companion, one-on-one coaching, meal plans, fitness program). Trade-offs: billing is 12 weeks upfront — not month-to-month — and the cancellation process is more involved than most competitors. For patients who have insurance that may cover brand-name tirzepatide, Noom Med's insurance navigation is a meaningful advantage. For patients paying out-of-pocket for compounded medications, RNK Health's all-in pricing is lower and the commitment structure is more flexible.

Henry Meds

Henry Meds is the no-frills option: no coaching, no membership fee, cash-pay only (no insurance), extremely simple intake. Pricing varies by dose and format; with promotional coupon codes, compounded semaglutide can start below $150/month. The trade-off is complete absence of coaching or lifestyle support — it is medication access only. For a patient who has established habits, a clear protocol, and wants the lowest possible cost for medication access, Henry Meds is a rational choice. For a patient who wants guidance, accountability, and support through the adjustment and maintenance phases, the absence of coaching is a meaningful structural gap that Henry Meds does not fill.

Mochi Health

Mochi Health offers compounded semaglutide at a flat $99/month at any dose — the lowest verified pricing in the category for semaglutide at publication — with physician oversight and pharmacy fulfillment. Trade-offs: no coaching included at that price point, and the flat-rate model at a very low price point raises legitimate questions about the sustainability of physician oversight quality at scale. Not available in all states. For pure price minimization with physician oversight, Mochi Health is a competitive option. For a program that includes active coaching and lifestyle support, the $197/month RNK Health all-in price includes features that Mochi Health's base plan does not.

SynergyRx GLP-1

SynergyRx is one of the platforms our editorial team has reviewed independently on TotalCareMedical.com. It offers access to both compounded and FDA-approved brand-name GLP-1 medications when clinically appropriate, with telehealth consultation and home delivery. For patients who want the flexibility to access brand-name options alongside compounded medications based on physician evaluation, SynergyRx offers a broader medication access model than RNK Health. See our SynergyRx GLP-1 review for the full assessment.

TrimRx

TrimRx is a streamlined telehealth platform offering compounded semaglutide and tirzepatide with competitive pricing. Our editorial team reviewed TrimRx independently — see the TrimRx GLP-1 review for detailed assessment. For patients comparing TrimRx and RNK Health specifically, the coaching inclusion and pharmacy disclosure at RNK Health are meaningful structural differences.

How to Decide: A Framework for Patients

The right platform depends on which of these patient profiles fits best. If brand-name medications with insurance coverage are a priority: evaluate Noom Med, WeightWatchers Clinic, or PlushCare — platforms with established insurance navigation infrastructure. If coaching and behavioral support are a priority and budget allows: RNK Health (coaching included, month-to-month) or Eden Health (24/7 coach access, 3-month commitment) are the strongest options in the compounded category. If the lowest possible price for medication access is the priority, with established habits already in place: Henry Meds or Mochi Health serve that profile. If flexibility — month-to-month, no prepay, cancel anytime — is essential: RNK Health's commitment model is among the most flexible in the category.

The question that should precede platform selection: Have I spoken with my primary care provider about whether GLP-1 therapy is appropriate for my specific health situation? A telehealth platform intake process is a prescribing mechanism, not a comprehensive metabolic evaluation. These programs work best for patients who have had that broader conversation with a provider who knows their full health picture.

Frequently Asked Questions

How does RNK Health compare to Noom Med?

Noom Med offers brand-name tirzepatide with insurance navigation and a robust behavior app. Trade-offs include 12-week prepay billing. RNK Health offers compounded GLP-1s, month-to-month flexibility, coaching included, and lower all-in pricing — without brand-name medication access.

How does RNK Health compare to Eden Health?

Eden Health has flat-rate compounded pricing (no dose-tier increases), 24/7 coach access, and a 3-month prepay commitment. RNK Health is month-to-month with no prepay requirement — more flexible for patients uncertain about long-term commitment.

Does RNK Health offer brand-name GLP-1 medications?

Based on available information, RNK Health's programs center on compounded semaglutide and tirzepatide. Patients seeking brand-name medications with insurance support should evaluate Noom Med, WeightWatchers Clinic, or PlushCare.

Which GLP-1 platform is cheapest in 2026?

The lowest published compounded semaglutide rates start below $100/month (Mochi Health, with limitations). RNK Health's $197/month all-inclusive rate is competitive when coaching, supplies, and shipping are factored into the comparison rather than medication cost alone.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article provides educational information about the known side effect profile and safety considerations for GLP-1 receptor agonist medications. It does not constitute medical advice. Consult your healthcare provider before starting any prescription medication program. Compounded medications from RNK Health have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

Why a Dedicated Safety Article Matters Here

GLP-1 receptor agonist medications have one of the most-studied clinical profiles of any weight management medication class in recent history. That evidence base is an asset — it means the risk profile is not theoretical; it is documented, quantified, and categorized. A reader who understands this profile before starting makes better decisions about whether to start, how to manage the adjustment period, what symptoms warrant immediate provider contact, and what long-term considerations to build into their approach. This article organizes that information from the peer-reviewed literature and approved prescribing information for semaglutide and tirzepatide. It applies to RNK Health's compounded versions of these active ingredients with one caveat: the specific risk data comes from trials of brand-name, FDA-approved formulations. Compounded versions have the same active pharmaceutical ingredient but have not undergone independent efficacy and safety trials as finished products.

For the full RNK Health program review, see the complete editorial assessment. For the mechanism and trial data comparison, see the semaglutide vs. tirzepatide guide.

Serious Risks: The Black Box Warning

Both semaglutide and tirzepatide carry an FDA black box warning — the most serious warning category — regarding thyroid C-cell tumors. In animal studies (rodents), both medications caused dose-dependent and duration-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this risk applies to humans is unknown — human thyroid C-cells have GLP-1 receptors, but at lower density than rodents. No human cases of MTC have been definitively attributed to GLP-1 receptor agonist use in clinical trial populations to date.

The clinical implication is that GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). This is a screening question during the RNK Health intake process. Patients must answer it accurately. Contact your provider immediately if you develop any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath during treatment — these may be symptoms requiring thyroid evaluation.

Pancreatitis: The Risk and the Recognition

Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists in post-marketing surveillance, though a definitive causal relationship has not been established. Patients with a history of pancreatitis are typically counseled to avoid this medication class. Any severe abdominal pain that radiates to the back, is persistent, and is accompanied by nausea and vomiting during GLP-1 treatment should be evaluated promptly by a medical provider — do not assume it is routine GI side effects without ruling out pancreatitis.

Muscle Loss: The Underreported Risk

GLP-1 medications reduce total caloric intake by reducing appetite. When caloric intake is substantially reduced without adequate protein intake and resistance exercise, the body loses lean muscle mass alongside fat. This is not a drug-specific side effect — it is a physiology-level response to caloric deficit that applies to any weight loss intervention. But GLP-1 medications are effective enough at producing caloric deficit that the muscle loss risk is real and deserves proactive management rather than retrospective recognition.

Patients on GLP-1 therapy should discuss protein targets with their physician or coach — general guidance from obesity medicine professionals suggests a minimum of 1.2 grams of protein per kilogram of body weight per day during active weight loss, though individual targets vary. Resistance exercise three or more times per week helps preserve lean mass. This is one specific area where RNK Health's included coaching may provide real value — helping patients build and sustain the protein and exercise habits that protect their lean body composition during the weight loss phase.

Weight Regain After Stopping: Setting Accurate Expectations

Clinical evidence is unambiguous on this point: most patients who discontinue GLP-1 receptor agonist therapy regain a substantial portion of lost weight within months. A 1-year follow-up study of the STEP-1 trial (published in Diabetes, Obesity and Metabolism, 2022) found that participants who discontinued semaglutide regained two-thirds of the weight they had lost within 12 months of stopping. This is not a failure of the medication — it reflects the mechanism. GLP-1 medications manage a hormonal signaling pathway; when the medication stops, the signaling stops. Long-term weight management typically requires either continued medication, a sustained lifestyle foundation robust enough to maintain reduced intake independently, or both.

Before starting any GLP-1 program, including RNK Health's, patients should have this conversation explicitly with their physician: What is the plan for long-term maintenance? Is this a finite course with a defined exit strategy, or a long-term management tool? What lifestyle habits will be established during treatment to maximize durability of results? These are not hypothetical questions — they are planning questions that separate programs with long-term value from those that produce temporary outcomes.

Frequently Asked Questions

What are the most common side effects?

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort — predominantly during dose escalation and typically improving over time.

Who should not use GLP-1 medications?

Standard contraindications include personal or family history of medullary thyroid carcinoma or MEN 2, current or planned pregnancy, breastfeeding, history of pancreatitis, severe GI conditions, and end-stage kidney or liver disease. Full evaluation by a licensed physician is required.

What is the thyroid risk?

Animal studies showed thyroid C-cell tumors with GLP-1 medications. The relevance to humans is unknown. As a precaution, these medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Report any neck lumps, hoarseness, or swallowing difficulty to your provider immediately.

What should I do if I experience severe side effects?

Severe abdominal pain, persistent vomiting, signs of allergic reaction, chest pain, or vision changes require immediate provider contact — RNK Health patient support: (347) 588-2100 — or emergency care if severe.

Does stopping GLP-1 medication lead to weight regain?

Yes. Clinical evidence shows most patients regain significant weight after discontinuing GLP-1 therapy. Long-term maintenance planning — medication continuity, lifestyle foundation, or both — should be part of the starting conversation with your provider.

What monitoring should occur during treatment?

Baseline kidney and liver function, thyroid history screening, ongoing GI symptom monitoring especially during dose escalation, and blood glucose monitoring for diabetic or prediabetic patients. Discuss your monitoring plan with your RNK Health physician at the outset.

Is muscle loss a risk?

Yes. Caloric deficit from GLP-1 therapy can cause muscle loss alongside fat loss. Adequate protein intake and regular resistance exercise throughout treatment are the primary countermeasures. RNK Health's included coaching may help patients build these habits.

What are the injection site considerations?

Weekly subcutaneous injections in the abdomen, thigh, or upper arm. Rotate sites weekly. Mild itching, burning, or redness at the site is possible. RNK Health includes required supplies with each plan.

Editorial disclosure: TotalCareMedical.com is an independent health and wellness research publication. This article is for educational and informational purposes only and does not constitute medical advice. All medication decisions should be made in consultation with your licensed healthcare provider. Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

The Core Question

If you are considering RNK Health and have reached the point of choosing between compounded semaglutide and compounded tirzepatide, you are asking the right question. These are not equivalent medications — they work through different mechanisms, have different clinical trial profiles, and carry different price points within RNK Health's program structure. This article gives you the verified information needed to have a productive conversation with the physician who reviews your case. It does not make the choice for you. That is your physician's job.

For a full assessment of how RNK Health's program works, including coaching structure and pharmacy details, see the complete RNK Health review. For foundational context on what compounded GLP-1 medications are, see our plain-language GLP-1 explainer.

The Mechanism Difference: One Receptor vs. Two

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors — found in the pancreas, stomach, brain, liver, and other tissues — and activates the same signaling pathways that the body's naturally produced GLP-1 hormone activates. The effects include increased insulin secretion in response to glucose, reduced glucagon release, slowed gastric emptying, and reduced appetite through central nervous system signaling at the hypothalamus and brainstem.

Tirzepatide adds a second mechanism. It is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. GIP is another incretin hormone produced in the gut in response to food, with roles in insulin secretion, fat metabolism, and — when its receptor is activated pharmacologically in combination with GLP-1 — potentially enhanced effects on appetite regulation and energy balance. In simple terms: semaglutide works through one hormonal lock; tirzepatide works through two simultaneously.

The clinical significance of that second mechanism is not just theoretical — it showed up clearly in phase 3 trial data. But trial comparisons require careful interpretation, which the next section addresses.

What the Phase 3 Trials Show (and What They Don't)

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) was a randomized, double-blind, placebo-controlled trial of 68 weeks in 1,961 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received semaglutide 2.4 mg weekly plus lifestyle intervention or placebo plus lifestyle intervention. The semaglutide group lost an average of 14.9% of body weight from baseline; the placebo group lost 2.4%. This is peer-reviewed efficacy data for FDA-approved Wegovy at its approved dose.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) was a randomized, double-blind, placebo-controlled trial of 72 weeks in 2,539 adults with obesity or overweight with at least one comorbidity, without type 2 diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo — all combined with lifestyle intervention. Average weight loss was 15.0%, 19.5%, and 20.9% at the respective tirzepatide doses, versus 3.1% in the placebo group. This is peer-reviewed efficacy data for the active ingredient in FDA-approved Zepbound.

The critical interpretive point: these are two separate trials with similar but not identical patient populations, different trial durations, and different doses. They are not a head-to-head comparison. In the only direct head-to-head trial between the two molecules in type 2 diabetes patients (SURPASS-2, published in New England Journal of Medicine 2021), tirzepatide at all doses produced greater weight reduction than semaglutide 1 mg — but the weight loss indication uses a different (higher) semaglutide dose than was studied head-to-head. The takeaway is directional: tirzepatide's dual mechanism appears to produce greater average weight loss in clinical trials. The exact magnitude of that difference in a given patient is unknowable in advance.

Both sets of trials used brand-name, FDA-approved formulations — not compounded versions. No peer-reviewed trials have independently validated equivalent outcomes for compounded semaglutide or tirzepatide specifically. This is a scope caveat that applies to every compounded GLP-1 program, not just RNK Health's.

Pricing Within RNK Health's Program

At RNK Health, as of publication:

Injectable semaglutide: $197/month all-inclusive (medication, physician oversight, coaching, supplies, shipping). Oral semaglutide: $198/month all-inclusive. Injectable tirzepatide: $297/month all-inclusive.

The tirzepatide premium within RNK Health's program is $100/month over injectable semaglutide — $1,200/year. That is not a trivial sum, and it is a legitimate factor to weigh against the clinical profile difference. Whether that premium is appropriate for a given patient depends on their health history, starting BMI, comorbidities, prior treatment history, and physician recommendation. A provider who recommends tirzepatide for a patient with significant insulin resistance and type 2 diabetes is operating differently than one who recommends it as a first-line option for a patient with modest weight to lose. These are clinical judgments, not consumer choices.

The Oral Semaglutide Question

RNK Health's oral semaglutide option ($198/month) deserves separate examination. The FDA-approved oral semaglutide tablet (Rybelsus, approved for type 2 diabetes, not for weight management) uses a proprietary absorption enhancer — SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — that enables meaningful bioavailability of semaglutide when taken orally, under specific conditions (fasting, small amount of water, 30 minutes before food). Most compounded oral semaglutide formats — including dissolving tablets and lozenges — do not incorporate this technology.

What this means practically: the bioavailability of compounded oral semaglutide is not established by peer-reviewed pharmacokinetic studies. It may be lower than injectable compounded semaglutide. Patients who prefer to avoid injections should ask their physician specifically about the evidence base for the oral compounded format relative to the injectable option before choosing it on the basis of needle aversion alone. There may be an appropriate patient for oral compounded semaglutide — but that patient should make the choice with accurate information about the bioavailability question.

Questions to Bring to Your Physician Review

The RNK Health intake process ends with a licensed physician determining your eligibility and the appropriate medication. Making that conversation productive requires you to show up with the right questions. Based on the clinical landscape and the distinguishing features of these two options, the most useful question is: Do my comorbidities (if any) favor one mechanism over the other? Is my starting BMI or weight loss target one where the tirzepatide data's higher average weight loss is clinically meaningful for my situation, or is the semaglutide data's profile sufficient? Are there any elements of my medical history that make one option preferable or one a relative contraindication? Given my goals and history, does the $100/month cost difference favor starting with semaglutide and escalating only if response is insufficient?

These questions turn a prescribing encounter into a clinical conversation. They are also the questions that will tell you whether the physician reviewing your case is genuinely engaging with your history or running through a standardized algorithm. Both are informative.

Frequently Asked Questions

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one receptor pathway (GLP-1); tirzepatide activates two (GLP-1 and GIP). Phase 3 trial data shows tirzepatide produced greater average weight loss at its highest studied dose, though these were separate trials — not a direct head-to-head comparison in weight management populations.

Is tirzepatide better than semaglutide for weight loss?

In separate phase 3 trials, tirzepatide at 15 mg weekly produced average weight loss of approximately 20.9% over 72 weeks (SURMOUNT-1), while semaglutide at 2.4 mg weekly produced approximately 14.9% over 68 weeks (STEP-1). These were separate trials, not direct head-to-head comparisons. Individual response and tolerability vary.

Which costs more at RNK Health — semaglutide or tirzepatide?

As of publication, injectable semaglutide is $197/month and tirzepatide is $297/month at RNK Health, both all-inclusive. The $100/month difference should be weighed against clinical factors in conversation with your physician.

Can I switch between semaglutide and tirzepatide at RNK Health?

Medication changes require physician guidance. Switching involves restarting titration at a low dose and is a clinical decision based on individual response and goals.

What is the oral semaglutide option at RNK Health?

RNK Health offers oral dissolving semaglutide at $198/month. Most compounded oral formulations lack the SNAC absorption enhancer used in FDA-approved Rybelsus. Patients should ask their physician about bioavailability expectations before choosing the oral format.

How long does it take to see results?

Appetite reduction typically begins within the first weeks. In clinical trials of brand-name formulations, measurable weight loss appeared within four weeks, with most weight loss occurring in the first four to five months. Individual results with compounded versions may differ.